| EASL clinical practice guidelines: management of chronic hepatitis B virus infection European Association For The Study Of The Liver Journal of hepatology 57 (1), 167-185, 2012 | 3538 | 2012 |
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection European Association For The Study Of The Liver Journal of hepatology 60 (2), 392-420, 2014 | 871 | 2014 |
| Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine R Ling, D Mutimer, M Ahmed, EH Boxall, E Elias, GM Dusheiko, ... Hepatology 24 (3), 711-713, 1996 | 610 | 1996 |
| Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis GR Foster, WL Irving, MCM Cheung, AJ Walker, BE Hudson, S Verma, ... Journal of hepatology 64 (6), 1224-1231, 2016 | 580 | 2016 |
| Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus R Perrillo, H Hann, D Mutimer, B Willems, N Leung, WM Lee, A Moorat, ... Gastroenterology 126 (1), 81-90, 2004 | 555 | 2004 |
| Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 … M Manns, D Samuel, EJ Gane, D Mutimer, G McCaughan, M Buti, ... The Lancet Infectious Diseases 16 (6), 685-697, 2016 | 514 | 2016 |
| Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis L Grellier, D Mutimer, M Ahmed, D Brown, AK Burroughs, K Rolles, ... The Lancet 348 (9036), 1212-1215, 1996 | 472 | 1996 |
| Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis MCM Cheung, AJ Walker, BE Hudson, S Verma, J McLauchlan, ... Journal of hepatology 65 (4), 741-747, 2016 | 460 | 2016 |
| Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease J Parkes, P Roderick, S Harris, C Day, D Mutimer, J Collier, M Lombard, ... Gut 59 (9), 1245-1251, 2010 | 389 | 2010 |
| Management of antiviral resistance in patients with chronic hepatitis B S Locarnini, A Hatzakis, J Heathcote, EB Keeffe, TJ Liang, D Mutimer, ... Antiviral therapy 9 (5), 679-693, 2004 | 372 | 2004 |
| Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens SJ Yeaman, DJ Danner, DJ Mutimer, SPM Fussey, OFW James, ... The Lancet 331 (8594), 1067-1070, 1988 | 355 | 1988 |
| Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C M Wali, RF Harrison, PJ Gow, D Mutimer Gut 51 (2), 248-252, 2002 | 316 | 2002 |
| Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians P Arends, MJ Sonneveld, R Zoutendijk, I Carey, A Brown, M Fasano, ... Gut 64 (8), 1289-1295, 2015 | 227 | 2015 |
| Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis R Zoutendijk, JGP Reijnders, F Zoulim, A Brown, DJ Mutimer, K Deterding, ... Gut 62 (5), 760-765, 2013 | 219 | 2013 |
| Central venous cannulation in patients with liver disease and coagulopathy–a prospective audit NC Fisher, DJ Mutimer Intensive care medicine 25, 481-485, 1999 | 209 | 1999 |
| Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response R Zoutendijk, JGP Reijnders, A Brown, F Zoulim, D Mutimer, K Deterding, ... Hepatology 54 (2), 443-451, 2011 | 199 | 2011 |
| Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up D Mutimer, G Dusheiko, C Barrett, L Grellier, M Ahmed, G Anschuetz, ... Transplantation 70 (5), 809-815, 2000 | 194 | 2000 |
| High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation D Mutimer, D Pillay, E Dragon, H Tang, M Ahmed, K O'Donnell, J Shaw, ... Journal of hepatology 30 (4), 715-721, 1999 | 192 | 1999 |
| Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection N Reau, PY Kwo, S Rhee, RS Brown Jr, K Agarwal, P Angus, E Gane, ... Hepatology 68 (4), 1298-1307, 2018 | 191 | 2018 |
| Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus DJ Mutimer, B Gunson, J Chen, J Berenguer, P Neuhaus, D Castaing, ... Transplantation 81 (1), 7-14, 2006 | 183 | 2006 |
